Endocrine therapy of HER-2/neu negative metastatic breast cancer - revising the bookshelf

被引：0
|
作者：
Lueftner, D. [1 ]
机构：
[1] Charite Campus Benjamin Franklin, Med Klin Hamatol Onkol & Tumorimmunol MS, Berlin, Germany
来源：
ONKOLOGIE | 2012年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：38 / 39
页数：2
相关论文
共 50 条
  • [41] Targeting HER-2/neu with antirat Neu virosomes for cancer therapy
    Waelti, E
    Wegmann, N
    Schwaninger, R
    Wetterwald, A
    Wingenfeld, C
    Rothen-Rutishauser, B
    Gimmi, CD
    CANCER RESEARCH, 2002, 62 (02) : 437 - 444
  • [42] Improved survival supports primary endocrine therapy in patients with hormone receptor positive/ HER-2 negative metastatic breast cancer.
    Shenk, Robert
    Cao, Lifen
    Bliggenstorfer, Jonathan T.
    Martin, James Michael
    Miller, Megan E.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [43] Clinical outcome of adjuvant endocrine treatment according to Her-2/neu status in breast cancer
    James, Rani
    Thriveni, K.
    Krishnamoorthy, Lakshmi
    Deshmane, Vijayalaxmi
    Bapsy, P. P.
    Ramaswamy, Girija
    INDIAN JOURNAL OF MEDICAL RESEARCH, 2011, 133 (01) : 70 - 75
  • [44] Correlation of serum HER-2/neu extracellular domain levels in metastatic breast cancer with the expression of HER-2/neu determined by immunohistochemistry in primary tumors.
    Witzel, I
    Thomssen, C
    Pantel, K
    Neumann, R
    Carney, W
    Loening, T
    Jaenicke, F
    Mueller, V
    BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 : S143 - S143
  • [45] Her-2/neu amplification in the metastatic breast carcinomas from patients with Her-2/neu overexpressing or nonexpressing primary carcinoma.
    Xu, RL
    Perle, A
    Inghirami, G
    Chan, W
    Delgado, Y
    Feiner, H
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2000, 114 (04) : 656 - 657
  • [46] Targeted Therapy in Metastatic Breast Cancer: The HER2/neu Oncogene
    Harbeck, Nadia
    Pegram, Mark D.
    Rueschoff, Josef
    Moebus, Volker
    BREAST CARE, 2010, 5 : 3 - 7
  • [47] Chromosome 17 polysomy and Her-2/neu status in metastatic breast cancer patients indicated to trastuzumab therapy.
    Hajduch, M
    Trojanec, R
    Bouchalova, K
    Kolar, Z
    Petrakova, K
    Cwiertka, K
    Svoboda, M
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 857S - 857S
  • [48] Patients with elevated serum HER-2/neu show increased response to Herceptin therapy in metastatic breast cancer.
    Schwartz, MK
    Ghani, F
    Dnistrian, AM
    Kish, L
    Schwartz, DC
    Armstrong, G
    CLINICAL CHEMISTRY, 2002, 48 (06) : A20 - A20
  • [49] EGFR activity in HER-2 over-expressing metastatic breast cancer:: Evidence for simultaneous phosphorylation of Her-2/neu and EGFR
    Gschwantler-Kaulich, D
    Hudelist, G
    Koestler, WJ
    Czerwenka, K
    Mueller, R
    Helmy, S
    Ruecklinger, E
    Kubista, E
    Singer, CF
    ONCOLOGY REPORTS, 2005, 14 (02) : 305 - 311
  • [50] Comparison of serum HER-2/neu levels and clinical response in metastatic breast cancer patients on Herceptin therapy.
    Kish, LA
    Goldblatt, J
    Neaman, I
    Levine, R
    Ghani, F
    Armstrong, G
    CLINICAL CHEMISTRY, 2001, 47 (06) : A132 - A132
12345